Jenburkt Pharma

Who are the top shareholders of the Jenburkt Pharma?

The top shareholders of Jenburkt Pharma are Bhuta Holdings Private Limited with 13.96%, and individual investors who collectively own 43.55%. The largest public shareholder is Nirmala Vinodkumar Daga, holding 3.3%, with no institutional investors currently involved.

The top shareholders of Jenburkt Pharma include Bhuta Holdings Private Limited, which holds the highest stake at 13.96%. Additionally, individual investors collectively own 43.55% of the company. The highest public shareholder is Nirmala Vinodkumar Daga, with a holding of 3.3%. There are no institutional investors or mutual funds currently holding shares in the company.

What does Jenburkt Pharma do?

Jenburkt Pharmaceuticals Ltd. manufactures and markets specialty pharmaceutical formulations and healthcare products. As of March 2025, it reported net sales of 41 Cr and a net profit of 9 Cr, with a market cap of Rs 572 Cr.

Overview:<BR>Jenburkt Pharmaceuticals Ltd. is engaged in the manufacturing and marketing of specialty and high-quality pharmaceutical formulations and healthcare products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated in 1985, Jenburkt Pharmaceuticals Ltd. was established by the Bhuta family to diversify into the healthcare and pharmaceutical sector. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 41 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 9 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 572 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.48<BR>- Return on Equity: 20.33%<BR>- Price to Book: 3.66<BR><BR>Contact Details:<BR>Address: Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W) Mumbai Maharashtra : 400058 <BR>Tel: 91-22-66943121/67603603 <BR>Email: investor@jenburkt.com <BR>Website: http://www.jenburkt.com

Has Jenburkt Pharma declared dividend?

Yes, Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend, with an ex-date of July 23, 2024. Despite this significant dividend announcement, the dividend yield remains at 0%, while the company has shown strong price appreciation over various periods.

Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 153%<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 4.19%, with a dividend return of 0%, resulting in a total return of 4.19%.<BR><BR>Over the past year, the price return was 55.55%, with a dividend return of 0%, leading to a total return of 55.55%.<BR><BR>In the 2-year period, the price return was 79.44%, with a dividend return of 0%, culminating in a total return of 79.44%.<BR><BR>For the 3-year period, the price return was 135.81%, with a dividend return of 2.48%, resulting in a total return of 138.29%.<BR><BR>In the 4-year period, the price return was 150.9%, with a dividend return of 4.55%, leading to a total return of 155.45%.<BR><BR>Over the last 5 years, the price return was 238.92%, with a dividend return of 6.11%, culminating in a total return of 245.03%.<BR><BR>Overall, Jenburkt Pharmaceuticals Ltd. has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting positive performance in the company's stock value.

Who are the peers of the Jenburkt Pharma?

Jenburkt Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Kerala Ayurveda, Ind-Swift Labs, Albert David, and Medico Remedies. While Jenburkt Pharma has average management risk and below-average growth, its 1-year return is 39.46%, higher than Ind-Swift Labs but lower than Divi's Lab's 51.69%.

Peers: The peers of Jenburkt Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Kerala Ayurveda, Ind-Swift Labs., Albert David, and Medico Remedies.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Jenburkt Pharma, Albert David, Medico Remedies, and Accent Microcell. Below Average management risk is noted for Kerala Ayurveda, Ind-Swift Labs. and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Jenburkt Pharma, Kerala Ayurveda, Ind-Swift Labs., Albert David, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Jenburkt Pharma, and Albert David, while Good capital structure is noted for Torrent Pharma and Medico Remedies, and Below Average capital structure is found at Kerala Ayurveda and Ind-Swift Labs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ind-Swift Labs. has the lowest at -21.31%. Jenburkt Pharma's 1-year return is 39.46%, which is significantly higher than Ind-Swift Labs. but lower than Divi's Lab. Additionally, Ind-Swift Labs. and Albert David have negative six-month returns.

Who are in the management team of Jenburkt Pharma?

As of March 2023, the management team of Jenburkt Pharma includes Ashish U Bhuta (Chairman & Managing Director), Dilip H Bhuta (Whole Time Director & CFO), and several Non-Executive & Independent Directors, including Bharat V Bhate, Rameshchandra J Vora, Arun R Raskapurwala, Hina Ravindra Mehta, and Sumit Ajaybhai Thakkar, along with Ashish R Shah (Company Secretary & Compliance Officer).

As of March 2023, the management team of Jenburkt Pharma includes the following individuals:<BR><BR>1. Bharat V Bhate - Non-Executive & Independent Director<BR>2. Rameshchandra J Vora - Non-Executive & Independent Director<BR>3. Arun R Raskapurwala - Non-Executive & Independent Director<BR>4. Ashish R Shah - Company Secretary & Compliance Officer<BR>5. Ashish U Bhuta - Chairman & Managing Director<BR>6. Dilip H Bhuta - Whole Time Director & CFO<BR>7. Hina Ravindra Mehta - Non-Executive & Independent Director<BR>8. Sumit Ajaybhai Thakkar - Independent Director<BR><BR>These individuals play various roles within the company's governance and management structure.

How big is Jenburkt Pharma?

As of 24th July, Jenburkt Pharmaceuticals Ltd. has a market capitalization of 581.00 Cr, with net sales of 151.70 Cr and a net profit of 32.07 Cr reported in the latest four quarters. The balance sheet for March 2025 shows shareholder's funds of 171.78 Cr and total assets of 194.72 Cr.

As of 24th July, Jenburkt Pharmaceuticals Ltd. has a market capitalization of 581.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Jenburkt Pharmaceuticals reported net sales of 151.70 Cr and a net profit of 32.07 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 171.78 Cr and total assets of 194.72 Cr.

Is Jenburkt Pharma overvalued or undervalued?

As of October 23, 2025, Jenburkt Pharma is considered overvalued with a PE ratio of 14.79 and an EV to EBIT of 12.31, despite outperforming the Sensex, indicating caution for potential investors.

As of 23 October 2025, Jenburkt Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 14.79, an EV to EBIT of 12.31, and an ROCE of 23.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.47, while Cipla is valued more attractively with a PE of 24.64.<BR><BR>The valuation metrics suggest that Jenburkt Pharma is trading at a premium relative to its earnings potential, especially when considering the PEG ratio of 0.94, which indicates growth at a reasonable price but still reflects a higher valuation compared to peers like Dr Reddy's Labs, which boasts a PE of 18.8 and an EV to EBITDA of 12.41. While Jenburkt Pharma has outperformed the Sensex over the past year with a return of 12.62% compared to the Sensex's 5.59%, the overall valuation suggests caution for potential investors.

How has been the historical performance of Jenburkt Pharma?

Jenburkt Pharma has shown consistent growth in net sales and profits, with net sales increasing from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, and profit after tax rising from INR 16.50 crore to INR 32.06 crore during the same period, indicating strong financial health.

Answer:<BR>The historical performance of Jenburkt Pharma shows a consistent growth trend in net sales and profits over the years.<BR><BR>Breakdown:<BR>Jenburkt Pharma's net sales have steadily increased from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, reflecting a strong upward trajectory. The total operating income followed a similar pattern, rising from INR 118.89 crore in March 2020 to INR 151.69 crore in March 2025. Operating profit (PBDIT) also saw significant growth, climbing from INR 24.15 crore in March 2021 to INR 47.11 crore in March 2025, indicating improved operational efficiency. Profit before tax rose from INR 21.64 crore in March 2021 to INR 43.93 crore in March 2025, while profit after tax increased from INR 16.50 crore to INR 32.06 crore during the same period. The company's earnings per share (EPS) improved from INR 35.95 in March 2021 to INR 72.7 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 104.31 crore in March 2020 to INR 194.72 crore in March 2025, with total liabilities also increasing but at a controlled pace. Cash flow from operating activities improved significantly, reaching INR 27 crore in March 2025, compared to INR 8 crore in March 2024, while the closing cash and cash equivalents rose to INR 7 crore in March 2025 from INR 4 crore in March 2024. Overall, Jenburkt Pharma has demonstrated robust financial health and growth across multiple dimensions over the years.

Is Jenburkt Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish, indicated by daily moving averages and monthly MACD, despite mixed signals from the KST and a lack of strong bullish indicators in the RSI and Dow Theory.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the monthly MACD showing a mildly bearish outlook. The weekly Bollinger Bands also reflect a bearish trend, while the KST presents a mixed view with a mildly bullish weekly signal but a mildly bearish monthly signal. Overall, the lack of strong bullish signals in the RSI and Dow Theory further supports the mildly bearish stance.

When is the next results date for Jenburkt Pharmaceuticals Ltd.?

The next results date for Jenburkt Pharmaceuticals Ltd. is 05 May 2026.

The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for 05 May 2026.

Should I buy, sell or hold Jenburkt Pharmaceuticals Ltd.?

Why is Jenburkt Pharmaceuticals Ltd. falling/rising?

As of 05-May, Jenburkt Pharmaceuticals Ltd. has seen its stock price rise to 1,074.50, reflecting a 3.1% increase and outperforming its sector. Despite a slight decline in delivery volume, the stock has shown positive returns over various periods, including a 137.17% increase over five years.

As of 05-May, Jenburkt Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 1,074.50, which reflects an increase of 32.3 points or 3.1%. This upward movement is notable as the stock has outperformed its sector by 3.25% today and has shown a trend reversal after two consecutive days of decline. Additionally, the stock reached an intraday high of Rs 1119.2, marking a significant increase of 7.39%.<BR><BR>In terms of performance over various periods, the stock has demonstrated positive returns, such as a 3.07% increase over the past week and a 6.08% increase over the past month, both outperforming the Sensex during these timeframes. Furthermore, the stock has shown substantial growth over the longer term, with a 50.72% increase over three years and a remarkable 137.17% increase over five years.<BR><BR>However, it is important to note that there are some concerns regarding investor participation, as the delivery volume has decreased by 0.82% compared to the five-day average, indicating a potential decline in investor interest. Despite this, the overall positive performance today and the recent trend reversal contribute to the stock's rising price.

Which are the latest news on Jenburkt Pharma?

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

Jenburkt Pharmaceuticals Ltd. reported strong Q4 FY26 results, with a net profit of ₹10.85 crores, an 82.97% quarter-on-quarter increase, and a revenue of ₹44.63 crores, reflecting solid growth. The company also improved its operating margins significantly and maintains a debt-free balance sheet, indicating a positive financial position overall.

Jenburkt Pharmaceuticals Ltd. has reported strong results for Q4 FY26, indicating a positive performance overall. The company achieved a net profit of ₹10.85 crores, which marks an impressive 82.97% increase compared to the previous quarter and a 27.05% increase year-on-year. This significant growth in net profit is complemented by a revenue of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% and an 8.72% increase year-on-year.<BR><BR>One of the standout features of this quarter is the remarkable recovery in operating margins, which rose to 31.93%, up from 17.25% in the previous quarter. This increase of 1,468 basis points is primarily attributed to a substantial reduction in employee costs, suggesting improved operational efficiency.<BR><BR>Overall, the financial performance showcases strong capital efficiency, with a return on equity (ROE) of 18.99%. The company's debt-free balance sheet further enhances its financial stability. Given these results, Jenburkt Pharmaceuticals appears to be in a good position, demonstrating both profitability and effective cost management. However, the sustainability of these margins and revenue growth will be crucial to monitor in future quarters.